The effect of moxifloxacin on the normal human cornea

Kendall Donaldson, Fabiana B. Marangon, Lauren Schatz, Anna S. Venkatraman, Eduardo C Alfonso

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To investigate the effects of moxifloxacin on the cornea of normal human eyes using confocal microscopy and slit-lamp biomicroscopy. Methods: This study enrolled adult volunteers who had a normal baseline ophthalmic examination. The dose regimen, similar to that of patients undergoing cataract extraction, was one drop of moxifloxacin in one eye four times a day for 3 days. The untreated fellow eye served as the control. Subjects had a baseline examination (Visit 1), started moxifloxacin the next day, and were examined 24 h (Visit 2) and 72 h (visit 3) after starting medication. At each visit, visual acuity and adverse effects were recorded, slit-lamp examination with fluorescein was used to measure tear break-up time, and endothelial and epithelial cell counts were determined using confocal microscopy. Results: Fifteen volunteers (mean age 37 ± 7 years) enrolled. No significant difference In visual acuity, tear break-up time, endothelial or epithelial cell counts was noted between the treated and fellow eye. Subjects experienced no significant decrease in visual acuity, tear break-up time, or endothelial cell counts during the 3-day treatment period in either eye. Epithelial cell counts were stable at Visits 1 and 2, and decreased similarly in the treated and control eye at Visit 3. Conclusions: Moxifloxacin was safe for use during the 3-day treatment period. Moxifloxacin causes no significant epithelial or endothelial toxicity, and has no effect on visual acuity or ocular surface integrity in healthy subjects treated using a dosing regimen that simulated prophylactic use following cataract surgery.

Original languageEnglish
Pages (from-to)2073-2078
Number of pages6
JournalCurrent Medical Research and Opinion
Volume22
Issue number10
DOIs
StatePublished - Oct 1 2006

Fingerprint

Cornea
Visual Acuity
Cell Count
Tears
Endothelial Cells
Epithelial Cells
Confocal Microscopy
Volunteers
Cataract Extraction
moxifloxacin
Fluorescein
Cataract
Healthy Volunteers
Therapeutics

Keywords

  • Confocal microscopy
  • Cornea
  • Moxifloxacin
  • Toxicity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effect of moxifloxacin on the normal human cornea. / Donaldson, Kendall; Marangon, Fabiana B.; Schatz, Lauren; Venkatraman, Anna S.; Alfonso, Eduardo C.

In: Current Medical Research and Opinion, Vol. 22, No. 10, 01.10.2006, p. 2073-2078.

Research output: Contribution to journalArticle

Donaldson, Kendall ; Marangon, Fabiana B. ; Schatz, Lauren ; Venkatraman, Anna S. ; Alfonso, Eduardo C. / The effect of moxifloxacin on the normal human cornea. In: Current Medical Research and Opinion. 2006 ; Vol. 22, No. 10. pp. 2073-2078.
@article{85ad9eaba1e64f6f8df122ed71ebc96a,
title = "The effect of moxifloxacin on the normal human cornea",
abstract = "Objective: To investigate the effects of moxifloxacin on the cornea of normal human eyes using confocal microscopy and slit-lamp biomicroscopy. Methods: This study enrolled adult volunteers who had a normal baseline ophthalmic examination. The dose regimen, similar to that of patients undergoing cataract extraction, was one drop of moxifloxacin in one eye four times a day for 3 days. The untreated fellow eye served as the control. Subjects had a baseline examination (Visit 1), started moxifloxacin the next day, and were examined 24 h (Visit 2) and 72 h (visit 3) after starting medication. At each visit, visual acuity and adverse effects were recorded, slit-lamp examination with fluorescein was used to measure tear break-up time, and endothelial and epithelial cell counts were determined using confocal microscopy. Results: Fifteen volunteers (mean age 37 ± 7 years) enrolled. No significant difference In visual acuity, tear break-up time, endothelial or epithelial cell counts was noted between the treated and fellow eye. Subjects experienced no significant decrease in visual acuity, tear break-up time, or endothelial cell counts during the 3-day treatment period in either eye. Epithelial cell counts were stable at Visits 1 and 2, and decreased similarly in the treated and control eye at Visit 3. Conclusions: Moxifloxacin was safe for use during the 3-day treatment period. Moxifloxacin causes no significant epithelial or endothelial toxicity, and has no effect on visual acuity or ocular surface integrity in healthy subjects treated using a dosing regimen that simulated prophylactic use following cataract surgery.",
keywords = "Confocal microscopy, Cornea, Moxifloxacin, Toxicity",
author = "Kendall Donaldson and Marangon, {Fabiana B.} and Lauren Schatz and Venkatraman, {Anna S.} and Alfonso, {Eduardo C}",
year = "2006",
month = "10",
day = "1",
doi = "10.1185/030079906X132668",
language = "English",
volume = "22",
pages = "2073--2078",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - The effect of moxifloxacin on the normal human cornea

AU - Donaldson, Kendall

AU - Marangon, Fabiana B.

AU - Schatz, Lauren

AU - Venkatraman, Anna S.

AU - Alfonso, Eduardo C

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Objective: To investigate the effects of moxifloxacin on the cornea of normal human eyes using confocal microscopy and slit-lamp biomicroscopy. Methods: This study enrolled adult volunteers who had a normal baseline ophthalmic examination. The dose regimen, similar to that of patients undergoing cataract extraction, was one drop of moxifloxacin in one eye four times a day for 3 days. The untreated fellow eye served as the control. Subjects had a baseline examination (Visit 1), started moxifloxacin the next day, and were examined 24 h (Visit 2) and 72 h (visit 3) after starting medication. At each visit, visual acuity and adverse effects were recorded, slit-lamp examination with fluorescein was used to measure tear break-up time, and endothelial and epithelial cell counts were determined using confocal microscopy. Results: Fifteen volunteers (mean age 37 ± 7 years) enrolled. No significant difference In visual acuity, tear break-up time, endothelial or epithelial cell counts was noted between the treated and fellow eye. Subjects experienced no significant decrease in visual acuity, tear break-up time, or endothelial cell counts during the 3-day treatment period in either eye. Epithelial cell counts were stable at Visits 1 and 2, and decreased similarly in the treated and control eye at Visit 3. Conclusions: Moxifloxacin was safe for use during the 3-day treatment period. Moxifloxacin causes no significant epithelial or endothelial toxicity, and has no effect on visual acuity or ocular surface integrity in healthy subjects treated using a dosing regimen that simulated prophylactic use following cataract surgery.

AB - Objective: To investigate the effects of moxifloxacin on the cornea of normal human eyes using confocal microscopy and slit-lamp biomicroscopy. Methods: This study enrolled adult volunteers who had a normal baseline ophthalmic examination. The dose regimen, similar to that of patients undergoing cataract extraction, was one drop of moxifloxacin in one eye four times a day for 3 days. The untreated fellow eye served as the control. Subjects had a baseline examination (Visit 1), started moxifloxacin the next day, and were examined 24 h (Visit 2) and 72 h (visit 3) after starting medication. At each visit, visual acuity and adverse effects were recorded, slit-lamp examination with fluorescein was used to measure tear break-up time, and endothelial and epithelial cell counts were determined using confocal microscopy. Results: Fifteen volunteers (mean age 37 ± 7 years) enrolled. No significant difference In visual acuity, tear break-up time, endothelial or epithelial cell counts was noted between the treated and fellow eye. Subjects experienced no significant decrease in visual acuity, tear break-up time, or endothelial cell counts during the 3-day treatment period in either eye. Epithelial cell counts were stable at Visits 1 and 2, and decreased similarly in the treated and control eye at Visit 3. Conclusions: Moxifloxacin was safe for use during the 3-day treatment period. Moxifloxacin causes no significant epithelial or endothelial toxicity, and has no effect on visual acuity or ocular surface integrity in healthy subjects treated using a dosing regimen that simulated prophylactic use following cataract surgery.

KW - Confocal microscopy

KW - Cornea

KW - Moxifloxacin

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=33750503796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750503796&partnerID=8YFLogxK

U2 - 10.1185/030079906X132668

DO - 10.1185/030079906X132668

M3 - Article

C2 - 17022866

AN - SCOPUS:33750503796

VL - 22

SP - 2073

EP - 2078

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 10

ER -